Cerebral venous thrombosis accounts for 0.5% to 3% of all strokes. The most vulnerable
populations include young individuals, women of reproductive age, and patients with a …

Abstract Purpose of Review Cerebral venous thrombosis (CVT) is a rare cause of stroke that
most commonly affects younger women. Here, we review new literature relevant to the …

During a 2-week period, we have encountered five cases presenting with the combination of
cerebral venous thrombosis (CVT), intracerebral hemorrhage and thrombocytopenia. A …

Background Recanalization in cerebral venous thrombosis (CVT) can begin as early as 1
week after initiating therapeutic anticoagulation. The clinical significance of recanalization …

Background: Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic
thrombocytopenia (VITT) is a severe condition, with high in-hospital mortality rates. Here, we …

Introduction: Previous reports and meta-analyses derived from small case series reported a
mortality rate of up to 40% in patients with coronavirus disease 2019 associated cerebral …

Purpose of review Cerebral venous thrombosis management has significantly evolved over
the past decades. While anticoagulation (AC) use is widely accepted in treating CVT …

BACKGROUND AND PURPOSE: Assessment of cerebral venous sinus thrombosis on MR
imaging can be challenging. The aim of this study was to evaluate the diagnostic accuracy of …

Vitamin K antagonists (VKAs) are the standard oral anti‐coagulant treatment for patients with
cerebral venous thrombosis (CVT). However, the direct oral anti‐coagulants (DOACs) …

Background Current methods to evaluate the severity of cerebral venous sinus thrombosis
(CVST) lack patient-specific indexes. Herein, a novel scoring method was investigated to …